Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells

British Journal of Dermatology

Volumn 167, Issue 2, 2012, Pages 348-358

  Felcht, M ^a,b   Heck, M ^a,b   Weiss, C ^b   Becker, J C ^a,c,d   Dippel, E ^a,e   Muller C S L ^a,f   Nashan, D ^a,g,h   Sachse, M M ^a,i   Nicolay, J P ^a,b   Booken, N ^a,b   Goerdt, S ^a,b   Klemke, C D ^a,b  

^a Working Group of Cutaneous Lymphomas of the Arbeitsgemeinschaft für Dermatologische Forschung   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e KLINIKUM LUDWIGSHAFEN   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h Hospital of Dortmund   (Germany)

ⁱ Hospital of Bremen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

AGED; AGED, 80 AND OVER; ANTIGENS, CD4; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84864418082     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10987.x     Document Type: Article

References (49)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification of cutaneous lymphomas. Blood 2005; 105: 3768-85.
2. Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 2006; 24: 1376-82.
3. Senff NJ, Hoefnagel J, Neelis K, et al. Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 2007; 143: 1520-6.
4. Felcht M, Booken N, Stroebel P, et al. The value of molecular diagnostics in primary cutaneous B-cell lymphomas in the context of clinic, histology and immunohistochemistry. J Am Acad Dermatol 2011; 64: 135-43.
5. Zoi-Toli O, Meijer CJLM, Oudejans JJ, et al. Expression of Fas and Fas ligand in cutaneous B-cell lymphoma. J Pathol 1999; 189: 533-8.
6. van Galen JC, Hoefnagel JJ, Vermeer MH, et al. Profiling of apoptosis genes identifies distinct types of primary cutaneous large B cell lymphoma. J Pathol 2008; 215: 340-6.
7. Soltani-Arabshahi R, Leboeuf C, Rivet J, et al. Bcl-xL gene expression correlated with lower apoptotic cell numbers and shorter progression-free survival in PCFCL. J Invest Dermatol 2009; 129: 1703-9.
8. Carbonnelle A, Martin-Garcia N, Ortonne N, et al. Study of the reactive dendritic cells in small B-cell lymphoproliferations of the skin. Virchows Arch 2007; 450: 441-7.
9. Edinger JT, Kant JA, Swerdlow SH,. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. Am J Surg Pathol 2010; 34: 1830-41.
10. Shevach EM,. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30: 636-45.
11. Wang HY, Wang RF,. Regulatory T cells and cancer. Curr Opin Immunol 2007; 19: 217-23.
12. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490-500.
13. Nishikawa H, Sakaguchi S,. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127: 759-67.
14. Campbell DJ, Koch MA,. Phenotypical and functional specialization of FOXP3(+) regulatory T cells. Nat Rev Immunol 2011; 11: 119-30.
15. Campbell DJ, Ziegler SF,. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Immunol 2007; 7: 305-10.
16. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373-80.
17. Sasada T, Kimura M, Yoshida Y, et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003; 98: 1089-99.
18. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
19. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538-43.
20. Kelley TW, Parker CJ,. CD4 (+)CD25(+)Foxp3(+) regulatory T cells and hematological malignancies. Front Biosci 2010; 1: 980-92.
21. Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11: 1467-73.
22. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissue uncovers variations in the tumor microenvironment and correlation with EBV infection and outcome. Blood 2008; 113: 2765-75.
23. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108: 2957-64.
24. Lee AM, Clear AJ, Calaminici M, et al. Number of CD4+ cells and location of forkhead box protein p3-positive cells in diagnostic follicular lymphoma tissue microarray correlates with outcome. J Clin Oncol 2006; 24: 5052-9.
25. Alvaro T, Lejeune M, Salvado MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24: 5350-7.
26. Farinha P, Al-Tourah A, Gill K, et al. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010; 115: 289-95.
27. Kim WY, Jeon YK, Kim TM, et al. Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol 2009; 20: 1688-96.
28. Klemke CD, Fritzsching B, Franz B, et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20: 1123-9.
29. Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease and survival. Leukemia 2007; 21: 2512-18.
30. Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations. Eur J Haematol 2008; 80: 483-9.
31. Kim FY, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-84.
32. Heid JB, Schmidt A, Oberle N, et al. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome. J Invest Dermatol 2009; 129: 2875-85.
33. Djemadji-Oudjiel N, Goerdt S, Kodelja V, et al. Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+3, MS-1+/-, 25F9-) in psoriatic dermis. Arch Dermatol Res 1996; 288: 757-64.
34. Becknell B, Caligiuri MA,. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005; 86: 209-39.
35. Zuo T, Wang L, Morrison C, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/Erb2 oncogene. Cell 2007; 129: 1275-86.
36. Krejsgaard T, Gjerdrum LM, Ralfkiaer E, et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. Leukemia 2008; 22: 2230-9.
37. Fritzsching B, Oberle N, Eberhardt N, et al. In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol 2005; 175: 32-6.
38. Kamarashev J, Schaerer L, Burg G, et al. Tumor-infiltrating T cells in primary cutaneous B-cell lympho-proliferative disorders. J Cutan Pathol 2001; 28: 448-52.
39. Lim HW, Hillsamer P, Kim CH,. Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J Clin Invest 2004; 114: 1640-9.
40. Lim HW, HIllsamer P, Banham AH, et al. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol 2005; 175: 4180-3.
41. Xystrakis E, Dejean AS, Bernard I, et al. Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood 2004; 104: 3294-301.
42. Bienvenu B, Martin B, Auffray C, et al. Peripheral CD8+CD25+ T lymphocytes from MHC class II-deficient mice exhibit regulatory activity. J Immunol 2005; 175: 246-53.
43. Berger CL, Tigelaar R, Cohen J, et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005; 105: 1640-7.
44. Hinz S, Pagerols-Raluy L, Oberg HH, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007; 67: 8344-50.
45. Karanikas V, Speletas M, Zamanakou M, et al. Foxp3 expression in human cancer cells. J Transl Med 2008; 22: 19.
46. Wang WH, Jiang CL, Yan W, et al. FOXP3 expression and clinical characteristics of hepatocellular carcinoma. World J Gastroenterol 2010; 16: 5502-9.
47. Noh J, Choi WS, Noh G, et al. Presence of Foxp3-expressing CD19(+)CD5(+) B cells in human peripheral blood mononuclear cells: human CD19(+)CD5(+)Foxp3(+) regulatory B cell (Breg). Immune Netw 2010; 10: 247-9.
48. Wang L, Liu R, Li W, et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009; 16: 336-46.
49. Allan SE, Passerini L, Bacchetta R, et al. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest 2005; 115: 3276-84.